https://scholars.lib.ntu.edu.tw/handle/123456789/604462
標題: | Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE | 作者: | Mamounas E. P. Untch M. Mano M. S. CHIUN-SHENG HUANG Geyer C. E. von Minckwitz G. Wolmark N. Pivot X. Kuemmel S. DiGiovanna M.P. Kaufman B. Kunz G. Conlin A.K. Alcedo J.C. Kuehn T. Wapnir I. Fontana A. Hackmann J. Polikoff J. Saghatchian M. Brufsky A. Yang Y. Zimovjanova M. Boulet T. Liu H. Tesarowski D. Lam L.H. Song C. Smitt M. Loibl S. |
關鍵字: | HER2; adjuvant; peripheral neuropathy; residual invasive early breast cancer; thrombocytopenia | 公開日期: | 2021 | 出版社: | ELSEVIER | 卷: | 32 | 期: | 8 | 起(迄)頁: | 1005 | 來源出版物: | Annals of oncology : official journal of the European Society for Medical Oncology | 摘要: | In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab. Here, we present additional exploratory safety and efficacy analyses. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/604462 | ISSN: | 0923-7534 | DOI: | 10.1016/j.annonc.2021.04.011 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。